George Lau to Humans
This is a "connection" page, showing publications George Lau has written about Humans.
Connection Strength
0.103
-
Reply to Grifoni et al. Clin Infect Dis. 2021 01 23; 72(1):183.
Score: 0.007
-
Letter to the Editor: Obesity, diabetes, non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease are proinflammatory hypercoagulable states associated with severe disease and thrombosis in Covid-19. Metabolism. 2021 02; 115:154437.
Score: 0.007
-
Reply to: "NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues". J Hepatol. 2021 02; 74(2):484-485.
Score: 0.007
-
Effect of COVID-19 on patients with compensated chronic liver diseases. Hepatol Int. 2020 Sep; 14(5):701-710.
Score: 0.007
-
Reply to: 'NAFLD or comorbidities, that is the question'. J Hepatol. 2020 09; 73(3):724-725.
Score: 0.007
-
Reply to: 'Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis'. J Hepatol. 2020 09; 73(3):722.
Score: 0.007
-
Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease'. J Hepatol. 2020 09; 73(3):718-719.
Score: 0.007
-
Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation. Hepatol Int. 2020 Jul; 14(4):432-436.
Score: 0.007
-
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol. 2020 08; 73(2):451-453.
Score: 0.007
-
Shortening the duration of therapy for chronic hepatitis C infection. Lancet Gastroenterol Hepatol. 2017 11; 2(11):832-836.
Score: 0.006
-
Shortening HCV therapy: science meets public health. Lancet Gastroenterol Hepatol. 2017 11; 2(11):771-772.
Score: 0.006
-
Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology. 2017 07; 66(1):13-26.
Score: 0.006
-
Treatment of chronic hepatitis B infection-2017. Liver Int. 2017 01; 37 Suppl 1:59-66.
Score: 0.006
-
APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19. Hepatol Int. 2020 Dec; 14(6):920-929.
Score: 0.002
-
COVID-19: Discovery, diagnostics and drug development. J Hepatol. 2021 01; 74(1):168-184.
Score: 0.002
-
Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score. Clin Infect Dis. 2020 09 12; 71(6):1393-1399.
Score: 0.002
-
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int. 2020 Sep; 14(5):690-700.
Score: 0.002
-
Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatol Int. 2020 Jul; 14(4):415-428.
Score: 0.002
-
Systemic inflammatory response syndrome in acute-on-chronic liver failure: Relevance of 'golden window': A prospective study. J Gastroenterol Hepatol. 2017 Dec; 32(12):1989-1997.
Score: 0.001
-
Diverse Changes of Circulating Fibroblast Growth Factor 21 Levels in Hepatitis B Virus-Related Diseases. Sci Rep. 2017 11 28; 7(1):16482.
Score: 0.001
-
Development of predisposition, injury, response, organ failure model for predicting acute kidney injury in acute on chronic liver failure. Liver Int. 2017 10; 37(10):1497-1507.
Score: 0.001
-
ANGPTL8 (Betatrophin) is Expressed in Visceral Adipose Tissue and Relates to Human Hepatic Steatosis in Two Independent Clinical Collectives. Horm Metab Res. 2017 May; 49(5):343-349.
Score: 0.001
-
Identification and characterization of a novel melanoma tumor suppressor gene on human chromosome 6q21. Clin Cancer Res. 2009 Feb 01; 15(3):797-803.
Score: 0.001